NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-55.65M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -106.62% |
| Return on Assets (Trailing 12 Months) | -85.20% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.82 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-11.29 |
| Earnings per Share (Most Recent Fiscal Year) | $-22.81 |
| Diluted Earnings per Share (Trailing 12 Months) | $-25.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 2.68M |
| Free Float | 2.32M |
| Market Capitalization | $14.08M |
| Average Volume (Last 20 Days) | 0.32M |
| Beta (Past 60 Months) | 1.25 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 42.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |